{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T05:17:23Z","timestamp":1739337443130,"version":"3.37.0"},"reference-count":45,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2025.1926","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:20:53Z","timestamp":1737379253000},"source":"Crossref","is-referenced-by-count":0,"title":["Telitacicept for systemic lupus erythematosus with post\u2011surgical papillary thyroid carcinoma: A case report"],"prefix":"10.3892","volume":"22","author":[{"given":"Jinhui","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, People's Hospital of Longhua, Shenzhen, Guangdong 518109, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Health Management, People's Hospital of Longhua, Shenzhen, Guangdong 518109, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linghua","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Health Management, Jiangmen Wuyi Hospital of Chinese Medicine, Jiangmen, Guangdong 529099, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, People's Hospital of Longhua, Shenzhen, Guangdong 518109, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"6021","key":"key20250211094247_b1-BR-22-3-01926","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236021","article-title":"Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"Ma","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"102736","key":"key20250211094247_b2-BR-22-3-01926","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"key20250211094247_b3-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"key20250211094247_b4-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"key20250211094247_b5-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"860794","key":"key20250211094247_b6-BR-22-3-01926","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860794","article-title":"Association between systemic lupus erythematosus and cancer morbidity and mortality: Findings from cohort studies","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"270","key":"key20250211094247_b7-BR-22-3-01926","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1760-3","article-title":"The risks of cancer development in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis","volume":"20","author":"Song","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"key20250211094247_b8-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jaut.2012.12.009","article-title":"Cancer risk in systemic lupus: an updated international multi-centre cohort study","volume":"42","author":"Bernatsky","year":"2013","journal-title":"J Autoimmun"},{"key":"key20250211094247_b9-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiol.2017171240","article-title":"Thyroid imaging reporting and data system (TI-RADS): A user's guide","volume":"287","author":"Tessler","year":"2018","journal-title":"Radiology"},{"key":"key20250211094247_b10-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20250211094247_b11-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1210\/jc.2009-0677","article-title":"Thyroid cancer in systemic lupus erythematosus: a case-control study","volume":"95","author":"Antonelli","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key20250211094247_b12-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1373\/clinchem.2004.044511","article-title":"Thyroglobulin antibodies in serum of patients with differentiated thyroid cancer: Relationship between epitope specificities and thyroglobulin recovery","volume":"51","author":"Okosieme","year":"2005","journal-title":"Clin Chem"},{"key":"key20250211094247_b13-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s10067-007-0568-3","article-title":"Estrogen receptor expression by peripheral blood mononuclear cells of patients with systemic lupus erythematosus","volume":"26","author":"Inui","year":"2007","journal-title":"Clin Rheumatol"},{"key":"key20250211094247_b14-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/path.2297","article-title":"The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas","volume":"214","author":"Zeng","year":"2008","journal-title":"J Pathol"},{"key":"key20250211094247_b15-BR-22-3-01926","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1177\/000313480907500908","article-title":"Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer","volume":"75","author":"Kansakar","year":"2009","journal-title":"Am Surg"},{"key":"key20250211094247_b16-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00002281-199909000-00005","article-title":"The role of sex hormones in systemic lupus erythematosus","volume":"11","author":"Lahita","year":"1999","journal-title":"Curr Opin Rheumatol"},{"key":"key20250211094247_b17-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/1529-0131(199810)41:10<1714::AID-ART3>3.0.CO;2-U","article-title":"Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus","volume":"41","author":"Cooper","year":"1998","journal-title":"Arthritis Rheum"},{"key":"key20250211094247_b18-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"key20250211094247_b19-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"key20250211094247_b20-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: Results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"key20250211094247_b21-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"key20250211094247_b22-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s10067-024-06992-7","article-title":"Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement","volume":"43","author":"Cheng","year":"2024","journal-title":"Clin Rheumatol"},{"key":"key20250211094247_b23-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/09612033231221911","article-title":"Efficacy of telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report","volume":"33","author":"Huang","year":"2024","journal-title":"Lupus"},{"key":"key20250211094247_b24-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/09612033241233021","article-title":"Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review","volume":"33","author":"Fan","year":"2024","journal-title":"Lupus"},{"key":"key20250211094247_b25-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1620\/tjem.2022.J074","article-title":"Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: A case report and review of the literature","volume":"258","author":"Ma","year":"2022","journal-title":"Tohoku J Exp Med"},{"key":"key20250211094247_b26-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000538033","article-title":"Telitacicept treatment refractory lupus nephritis: A case report","volume":"14","author":"Li","year":"2024","journal-title":"Case Rep Nephrol Dial"},{"key":"key20250211094247_b27-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis: A single-center, real-world retrospective study","volume":"28","author":"Huang","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"key20250211094247_b28-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: A real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"key":"key20250211094247_b29-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","article-title":"Systemic rheumatic diseases: From biological agents to small molecules","volume":"18","author":"Sarzi-Puttini","year":"2019","journal-title":"Autoimmun Rev"},{"key":"key20250211094247_b30-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/annrheumdis-2017-212086","article-title":"Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: A danish population-based cohort study","volume":"77","author":"Dreyer","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key20250211094247_b31-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British society for rheumatology biologics register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"R5","key":"key20250211094247_b32-BR-22-3-01926","doi-asserted-by":"publisher","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key20250211094247_b33-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: Should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"key20250211094247_b34-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s13555-022-00797-9","article-title":"Secukinumab in patients with psoriasis and a personal history of malignancy: A multicenter real-life observational study","volume":"12","author":"Pellegrini","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"key20250211094247_b35-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"key20250211094247_b36-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: A review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"key20250211094247_b37-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cgh.2023.07.027","article-title":"Risk of cancer recurrence in patients with immune-mediated diseases with use of immunosuppressive therapies: An updated systematic review and meta-analysis","volume":"22","author":"Gupta","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20250211094247_b38-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cgh.2011.09.017","article-title":"Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model","volume":"10","author":"Siegel","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20250211094247_b39-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.cgh.2014.07.058","article-title":"The benefit-to-risk balance of combining infliximab with azathioprine varies with age: A markov model","volume":"13","author":"Scott","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20250211094247_b40-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20250211094247_b41-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? A meta-analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"key20250211094247_b42-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1136\/gutjnl-2013-305300","article-title":"The management of immunosuppression in patients with inflammatory bowel disease and cancer","volume":"62","author":"Bernheim","year":"2013","journal-title":"Gut"},{"key":"key20250211094247_b43-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"key20250211094247_b44-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamaoto.2017.0550","article-title":"Development of a new clinical severity staging system for patients with nonmetastatic papillary thyroid carcinoma","volume":"143","author":"Karadaghy","year":"2017","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"key20250211094247_b45-BR-22-3-01926","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cncy.22618","article-title":"The Italian consensus for the classification and reporting of thyroid cytology: Cytohistologic and molecular correlations on 37,371 nodules from a single institution","volume":"130","author":"Torregrossa","year":"2022","journal-title":"Cancer Cytopathol"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T07:43:27Z","timestamp":1739259807000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2025.1926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,20]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2025.1926","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"type":"print","value":"2049-9434"},{"type":"electronic","value":"2049-9442"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"article-number":"48"}}